G lucagon-like peptide-1 receptor agonists, aka GLP-1 agonists, such as semaglutide -- better known as Ozempic -- have ...
Use of cystatin C for chronic kidney disease evaluation and sodium–glucose cotransporter-2 inhibitors as first-line therapy ...
Daily Maverick on MSN1d
New chronic kidney disease treatments show promise, but are expensive and inaccessibleWhile the exact number of people with chronic kidney disease in South Africa is unclear, estimates suggest it could be as ...
2d
Weight loss drugs like Ozempic deliver more health benefits than expected.
Chronic Kidney Disease is a silent killer that progresses gradually, often going unnoticed until the late stages. While ...
Research suggests potential health benefits beyond what popular diabetes and weight-loss drugs were first approved to treat.
With semaglutide shortages in the rearview, Novo Nordisk is doubling down on marketing efforts for its GLP-1 drugs.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback